Why the study?
Does intravenous tissue-type plasminogen activator induce coronary thrombolysis in a canine model of acute myocardial infarction?
Does intravenous tissue-type plasminogen activator induce coronary thrombolysis in a canine model of acute myocardial infarction?
Intravenous tissue-type plasminogen activator rapidly induces coronary thrombolysis and restores myocardial blood flow in a canine model without causing systemic fibrinolysis.
May inform human trial design for selective thrombolysis; leaves open translation to clinical coronary occlusion without systemic bleeding risk.
Coronary thrombolysis, an intervention that can abort the sequelae of acute myocardial infarction, was accomplished within 10 minutes in dogs by intravenous administration of clot-selective, tissue-type plasminogen activator. In addition to inducing clot lysis, this promising fibrinolytic agent restored intermediary metabolism and nutritional myocardial blood flow, detectable noninvasively with positron tomography, without inducing a systemic fibrinolytic state.
No takes yet. Share an insight, caveat, or question.
Bergmann et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: